KURA

Kura Oncology Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 0/10
  • Value↓ 0/10
Kura Oncology sales and earnings growth
KURA Growth
Low
  • Revenue Y/Y↑ 25.24%
  • EPS Y/Y↓ -57.43%
  • FCF Y/Y↓ -152.82%
Kura Oncology gross and profit margin trends
KURA Profitability
Fair
  • Gross margin ↑ 99.90%
  • EPS margin↓ -412.90%
  • ROIC 5Y↓ -39.28%
Kura Oncology net debt vs free cash flow
KURA Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -183.1

Kura Oncology stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks